The U.S. Supreme Court denied Agilent Technologies’ request to review invalidation of two CRISPR-related patents in its legal battle with Synthego. The denial leaves in place a Federal Circuit ruling that upheld a PTAB decision deeming Agilent’s patent claims on specific guide RNA (gRNA) chemical modifications unpatentable. The outcome effectively closes Agilent’s appeal path, clearing a material barrier for developers that rely on those gRNA modifications for CRISPR-Cas workflows. For the broader gene-editing ecosystem, the ruling reduces uncertainty around foundational CRISPR IP and may accelerate downstream research and therapeutic engineering that depends on optimized guide chemistry.